Loosen, Sven H., Schulze-Hagen, Max, Vucur, Mihael, Gorgulho, Joao, Paffenholz, Pia, Benz, Fabian, Mohr, Raphael, Demir, Munevver ORCID: 0000-0002-7050-797X, Wree, Alexander ORCID: 0000-0002-2968-1335, Kuhl, Christiane, Trautwein, Christian, Tacke, Frank, Bruners, Philipp ORCID: 0000-0002-5790-3687, Luedde, Tom and Roderburg, Christoph (2021). Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis. JGH Open, 5 (3). S. 356 - 364. HOBOKEN: WILEY. ISSN 2397-9070

Full text not available from this repository.

Abstract

Background and Aim Transarterial chemoembolization (TACE) represents a standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) or liver metastases. However, identification of the ideal candidates for TACE therapy remains challenging. The soluble urokinase plasminogen activator receptor (suPAR) has recently evolved as a prognostic marker in patients with cancer; however no data on suPAR in the context of TACE exists. Methods Serum levels of suPAR were measured by an enzyme-linked immunosorbent assay in n = 48 TACE patients (HCC: n = 38, liver metastases: n = 10) before intervention and 1 day after TACE, as well as in 20 healthy controls. Results Serum levels of suPAR were significantly elevated in patients with liver cancer compared to healthy controls. Patients with or without an objective tumor response to TACE therapy had comparable levels of circulating suPAR. Importantly, baseline suPARs above the ideal prognostic cut-off value (5.39 ng/mL) were a significant prognostic marker for reduced overall survival (OS) following TACE. As such, patients with initial suPAR levels >5.39 ng/mL showed a significantly reduced median OS of only 256 days compared to patients with suPAR serum levels below the cut-off value (median OS: 611 days). In line with previous data, suPAR serum concentrations correlated with those of creatinine but were independent of tumor entity, leukocyte count, and C-reactive protein in multivariate analysis. Conclusion Baseline suPAR serum levels provide important information on the postinterventional outcome of liver cancer patients receiving TACE.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Loosen, Sven H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schulze-Hagen, MaxUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vucur, MihaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gorgulho, JoaoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Paffenholz, PiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Benz, FabianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mohr, RaphaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Demir, MunevverUNSPECIFIEDorcid.org/0000-0002-7050-797XUNSPECIFIED
Wree, AlexanderUNSPECIFIEDorcid.org/0000-0002-2968-1335UNSPECIFIED
Kuhl, ChristianeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Trautwein, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tacke, FrankUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bruners, PhilippUNSPECIFIEDorcid.org/0000-0002-5790-3687UNSPECIFIED
Luedde, TomUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roderburg, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-595346
DOI: 10.1002/jgh3.12501
Journal or Publication Title: JGH Open
Volume: 5
Number: 3
Page Range: S. 356 - 364
Date: 2021
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 2397-9070
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
Gastroenterology & HepatologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/59534

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item